Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Pluristem Therapeutics Moving Into New State-of-the-art GMP Facility

RELATED NEWS
Trade PSTI now with 

Pluristem Therapeutics, Inc. (PSTI: Quote), a developer of placenta-based cell therapies, Wednesday said the company has taken possession of and is moving into its new state-of-the-art GMP facility.

The facility allows for the production of mass quantities of PLacental eXpanded or PLX cells that possess the advantages of being grown utilizing Pluristem's patented 3D bioreactor technology.

The new manufacturing facility will have the capability to produce different PLX product candidates with the potential capacity of over 150,000 doses annually.

The new facility allows increasing the yield from one placenta to over ten times the yield from the previous pilot facility.

Additionally, if regulators approve more indications for clinical trials, this new facility will enable the firm to supply PLX cells to conduct these additional trials in parallel.

Zami Aberman, Chairman and CEO of Pluristem said, "We are excited to begin work in our new plant. With this new manufacturing facility, our company is capable of combining the ideal characteristics of a supply source in the placenta with a proprietary expansion technology that successfully addresses the issues of reproducibility and cost to provide high numbers of reproducible batches of the highest quality PLX cells.''

Register
To receive FREE breaking news email alerts for Pluristem Therapeutics, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Beverages giant Coca-Cola Co. reported Tuesday a profit for the third quarter that decreased 14 percent from last year, despite higher worldwide volumes, reflecting a revenue drop. Adjusted earnings per share matched analysts' expectations, even as quarterly revenues missed their estimates. Following the announcement, the company's shares are trading more than five percent lower in early deals. Apple Inc. said Monday that its fourth quarter profit rose 13% from last year, driven by strong sales of its iPhones and Mac computers. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly sales. At the same time, the company gave an upbeat revenue forecast for the current quarter, which includes the all important holiday season. Programmable chipmaker Xilinx Inc. (XLNX) said Thursday after the markets closed that its second quarter profit rose 21% from last year, helped by higher revenue and better cost control. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue....
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.